Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. VCEL
VCEL logo

VCEL Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Vericel Corp (VCEL) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
40.100
1 Day change
2.48%
52 Week Range
45.970
Analysis Updated At
2026/06/12
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

VCEL is not a good immediate buy for a beginner long-term investor with $50,000-$100,000 who is impatient and wants a clear entry now. The stock has constructive long-term analyst support and strong growth commentary, but the current technical setup is stretched near resistance, options positioning is extremely bullish, and there is no recent news or fresh financial data to confirm a new upside catalyst. My direct view: hold for now rather than buy today.

Technical Analysis

VCEL is trading at 38.23, just below the first resistance level at 38.409 and above the pivot at 35.72. MACD histogram is positive and expanding, which supports short-term upward momentum. However, RSI_6 is 75.117, indicating the stock is extended and not an attractive fresh entry right now. Moving averages are converging, suggesting the trend is not in a strong, clean breakout phase yet. Overall technicals are bullish but short-term stretched, with resistance overhead at 38.41 and 40.07.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Options sentiment is very bullish. Call open interest (1042) is far higher than put open interest (116), and today’s volume is overwhelmingly call-driven with a put-call volume ratio of 0.02. Implied volatility is elevated at 96.26, while IV rank is 31.64 and IV percentile is 9.13, suggesting options are pricing in meaningful movement. This supports upside sentiment, but the bullishness is already crowded.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
4
Buy
11

Positive Catalysts

  • Analysts remain constructive overall, with H.C. Wainwright raising its target to $70 and maintaining Buy, and Truist also keeping Buy while highlighting above-20% growth prospects and improving profitability. Options flow is strongly bullish. The stock also has a favorable longer-term growth narrative based on analyst commentary.

Neutral/Negative Catalysts

  • No news in the recent week means no fresh catalyst to push the stock higher immediately. The share price is near resistance, RSI is extended, and similar candlestick pattern analysis suggests near-term weakness over the next week and month. Hedge fund and insider activity are neutral, so there is no strong sponsorship signal from those groups. Financial snapshot data is missing, limiting confirmation of latest-quarter performance.

Financial Performance

Latest quarter financial data was not available due to an error in the snapshot, so there is no confirmed revenue or earnings update to assess directly. Based on analyst commentary, the company is still viewed as having above-20% growth prospects and emerging/accelerating profitability, which is positive for a long-term thesis. However, without the latest quarter season and reported figures, the current quarter performance cannot be verified from the provided data.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analyst tone is positive overall but slightly mixed on target changes. H.C. Wainwright raised the target to $70 from $64 and kept Buy after Q1, while Truist lowered its target to $42 from $48 but also kept Buy ahead of Q1. The Wall Street pro view is that VCEL has strong growth potential and improving profitability; the con view is that targets have not moved uniformly higher, implying some caution around near-term execution and valuation.

Wall Street analysts forecast VCEL stock price to rise
5 Analyst Rating
Wall Street analysts forecast VCEL stock price to rise
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 39.130
sliders
Low
55
Averages
57.67
High
60
Current: 39.130
sliders
Low
55
Averages
57.67
High
60
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$64 -> $70
AI Analysis
2026-05-08
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$64 -> $70
AI Analysis
2026-05-08
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Vericel to $70 from $64 and keeps a Buy rating on the shares following the Q1 report.
Truist
Buy
downgrade
$48 -> $42
2026-04-15
Reason
Truist
Price Target
$48 -> $42
2026-04-15
downgrade
Buy
Reason
Truist lowered the firm's price target on Vericel to $42 from $48 but keeps a Buy rating on the shares as part of a broader research note previewing Q1 results in MedTech. The firm expects Q1 performances to be in line or better than what feels like an anxious investor sentiment around Q1 volumes, the analyst tells investors in a research note. Truist adds that the stock should be able to sustain a premium relative to its SMID peers given the company's above-20% growth prospects and emerging/accelerating profitability.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for VCEL
Unlock Now

People Also Watch